Las Vegas, Nevada
CNS clinical trials in Las Vegas, NV
45 CNS studies are recruiting participants at sites in Las Vegas as of November 16, 2026, according to ClinicalTrials.gov. CNS Clinical Research can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Las Vegas at a glance
- 45 studies are recruiting at a site in Las Vegas.
- By phase: Phase 2 (13), Phase 3 (22), Phase 4 (5), No phase (2), Observational (3). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (41), university, hospital or other (4).
- By research area: Depression (16), Parkinson's Disease (8), ADHD (6), Migraine (6), Schizophrenia (6), Multiple Sclerosis (3).
- Most recent update to one of these records: November 16, 2026.
Depression studies recruiting in Las Vegas
Basic details from each study's public record (the 30 most recently updated of 45). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Study site
- Vector Clinical Trials
- Registry record
- NCT07226661 · updated
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Phase 3
- Ages 18 to 85
- All sexes
- Sponsor
- Cybin IRL Limited
- Study site
- Redbird Research, LLC
- Registry record
- NCT06793397 · updated
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Definium Therapeutics US, Inc.
- Study site
- Redbird Research
- Registry record
- NCT07592689 · updated
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Study site
- Redbird Research LLC
- Registry record
- NCT07284667 · updated
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Vector Clinical Trials
- Registry record
- NCT07412756 · updated
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Phase 3
- Ages 18 to 74
- All sexes
- Sponsor
- Janssen Research & Development, LLC
- Study site
- Vector Clinical Trials
- Registry record
- NCT07573176 · updated
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Tonix Pharmaceuticals, Inc.
- Registry record
- NCT07621237 · updated
Study of ALTO-300 in MDD
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Alto Neuroscience
- Registry record
- NCT05922878 · updated
ALTO-100 in Bipolar Disorder With Depression (BD-D)
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Alto Neuroscience
- Registry record
- NCT06656416 · updated
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Axsome Therapeutics, Inc.
- Registry record
- NCT07484217 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in Las Vegas, NV on ClinicalTrials.gov.
Schizophrenia studies recruiting in Las Vegas
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Phase 2
- Ages 55 to 90
- All sexes
- Sponsor
- MapLight Therapeutics
- Registry record
- NCT06887192 · updated
A Study to Evaluate the Effect of KarXT on Urological Safety
- Phase 4
- Ages 18 to 65
- All sexes
- Sponsor
- Bristol-Myers Squibb
- Study site
- IMA Clinical Research Las Vegas
- Registry record
- NCT07221877 · updated
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- Phase 3
- Ages 5 to 17
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- Clinical Research of Southern Nevada, LLC
- Registry record
- NCT06229210 · updated
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- MapLight Therapeutics
- Registry record
- NCT07459647 · updated
Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in Las Vegas, NV on ClinicalTrials.gov.
ADHD studies recruiting in Las Vegas
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
- Phase 3
- Ages 6 to 11
- All sexes
- Sponsor
- Axsome Therapeutics, Inc.
- Registry record
- NCT07717879 · updated
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
- Phase 3
- Ages 12 to 17
- All sexes
- Sponsor
- Axsome Therapeutics, Inc.
- Registry record
- NCT07717892 · updated
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
- Phase 3
- Ages 18 to 65
- All sexes
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Study site
- Center for Psychiatry and Behavioral Medicine. Inc.
- Registry record
- NCT07759154 · updated
A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- Alkermes, Inc.
- Study site
- Alkermes Investigational Site
- Registry record
- NCT07755410 · updated
Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in Las Vegas, NV on ClinicalTrials.gov.
Parkinson's disease studies recruiting in Las Vegas
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Comprehensive Cancer Centers of Nevada ( Site 0015)
- Registry record
- NCT06841354 · updated
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Optum Care Cancer Center ( Site 0050)
- Registry record
- NCT06966700 · updated
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Women's Cancer Center of Nevada ( Site 6011)
- Registry record
- NCT07216703 · updated
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Phase 3
- Ages 50 to 85
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- Cleveland Clinic Lou Ruvo
- Registry record
- NCT07174310 · updated
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
- Phase 2
- Ages 40 to 80
- All sexes
- Sponsor
- Neuron23 Inc.
- Study site
- Cleveland Clinic
- Registry record
- NCT06680830 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in Las Vegas, NV on ClinicalTrials.gov.
Multiple sclerosis (MS) studies recruiting in Las Vegas
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- Observational
- Ages 18 and older
- All sexes
- Sponsor
- TG Therapeutics, Inc.
- Study site
- TG Therapeutics Investigational Trial Site
- Registry record
- NCT06433752 · updated
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Phase 3
- Ages 40 to 70
- All sexes
- Sponsor
- Novartis Pharmaceuticals
- Study site
- Cleveland Clinic Foundation
- Registry record
- NCT06846281 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in Las Vegas, NV on ClinicalTrials.gov.
Migraine studies recruiting in Las Vegas
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study site
- Oasis Clinical Research
- Registry record
- NCT07816367 · updated
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study sites
- AMR Clinical - Las Vegas · Excel Clinical Research · IMA Clinical Research - Las Vegas
- Registry record
- NCT07645924 · updated
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Study sites
- AMR Clinical - Las Vegas · Excel Clinical Research · IMA Clinical Research - Las Vegas
- Registry record
- NCT07674654 · updated
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
- Phase 4
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study site
- M3 Wake Research - Las Vegas Rainbow
- Registry record
- NCT07609914 · updated
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
- Phase 2
- Ages 18 to 65
- All sexes
- Sponsor
- Aspeya, Inc.
- Study site
- M3 Wake Research - Las Vegas Rainbow
- Registry record
- NCT07646613 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in Las Vegas, NV on ClinicalTrials.gov.
Ask about studies near Las Vegas
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections